New CAR-T therapy aims to tackle childhood B-Cell cancers that Won't quit
NCT ID NCT06508931
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This phase 2 trial is testing a new CAR-T cell therapy called MB-CART2019.1 in 31 children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to prior treatments. The therapy uses the patient's own immune cells, modified to target two proteins (CD20 and CD19) on cancer cells. The study will measure how well the treatment shrinks tumors and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Robert Debré
ACTIVE_NOT_RECRUITINGParis, Boulevard Sérurier 48, 75019, France
-
IRCCS Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Piazza Sant Onofrio 4, 00165, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prinses Maxima Centrum
ACTIVE_NOT_RECRUITINGUtrecht, Heidelberglaan 25, Netherlands
-
Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie
ACTIVE_NOT_RECRUITINGMünster, Albert-Schweitzer-Campus 1, Gebaeude A1, 48129, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zamtocabtagene autoleucel (MB-CART2019.1), a type of CAR-T cell therapy that targets two proteins (CD20 and CD19) on cancer cells
What this could lead to
If successful, this could offer a new treatment option for children with aggressive B-cell cancers that have not responded to standard therapies, potentially leading to long-term disease control.
What could go wrong
This is an early-phase trial with only 31 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.